Jun 2026 (Q2 FY26) — Jul 30, 2026
Butterfly Network Q2 FY26 — Record Revenue and Gross Margin, Raised Full-Year Guidance
Read the full callButterfly Network (BFLY) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Butterfly Network earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 32.6 | +39.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -41.9 | +26.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -12.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$7.85 +3.29% · +$0.25
Performance +242.8% 1Y
1Y: $2.29 on 14 Oct 2025 → $7.85. High $9.93 (22 Sept 2026), low $1.97 (17 Nov 2025).
- Previous close
- $7.6
- 52-week range
- $1.97 – $9.93
- One year
- +232.63%
Overview
- Symbol
- BFLY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Butterfly Network earnings calls (BFLY)
Financials
What the filings say
Net profit, year on year: +7% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 22 | 21 | 23 | 21 | 32 | 27 | 33 |
| Operating profit | -17 | -17 | -18 | -16 | -35 | -17 | -14 | -14 |
| Operating margin | −83.9% | −77.5% | −87.0% | −68.8% | −163.5% | −53.0% | −52.3% | −41.9% |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -17 | -18 | -14 | -14 | -34 | -15 | -13 | -13 |
| Tax rate | −0.3% | 0.6% | −0.1% | −0.1% | −0.1% | −0.4% | 0.0% | 0.0% |
| Net profit | -17 | -18 | -14 | -14 | -34 | -15 | -13 | -13 |
| EPS ($ per share) | -0.08 | — | -0.06 | -0.06 | -0.13 | — | -0.05 | -0.05 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Reserves | — | -395 | -427 | -596 | -730 | -802 | -879 |
| Total liabilities | — | 148 | 124 | 92 | 84 | 87 | 101 |
| Fixed assets | — | 7 | 15 | 31 | 25 | 20 | 17 |
| Investments | — | — | — | 75 | — | — | — |
| Total assets | — | 147 | 572 | 418 | 304 | 256 | 297 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -120 | -82 | -189 | -169 | -99 | -42 | -13 |
| Cash from investing | -4 | -2 | -10 | -94 | 70 | -3 | -3 |
| Cash from financing | 0 | 54 | 566 | 3 | 0 | -1 | 78 |
| Net cash flow | -125 | -30 | 367 | -260 | -28 | -46 | 62 |
| Capital expenditure | -4 | -2 | -8 | -18 | -6 | -3 | -3 |
| Free cash flow | -125 | -84 | -197 | -187 | -105 | -44 | -16 |
Insider filings
104 filings between Nov 3, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
$13.07M
9 purchases by 2 insiders
Sales
$126.22M
79 sales by 9 insiders
57% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 15
- Award — granted as compensation
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| ROTHBERG JONATHAN M | — | $75.19M | Jul 22, 2026 |
| ROBBINS LARRY | $11.50M | $34.60M | Aug 17, 2026 |
| DEVIVO JOSEPH | — | $6.49M | Oct 6, 2026 |
| Cashman Steve | — | $5.93M | Sep 4, 2026 |
| Carlson Megan | — | $1.74M | Oct 2, 2026 |
| Phanstiel S. Louise | $1.57M | — | Aug 14, 2026 |
| Doherty John N. | — | $1.05M | Jul 20, 2026 |
| Ku Victor | — | $736.5K | Jul 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | DEVIVO JOSEPH President & CEO | Sale 10b5-1 plan | 35,790 | $358.6K |
| Oct 2, 2026 | Carlson Megan CAO and SVP, Finance | Sale | 10,114 | $88.4K |
| Sep 23, 2026 | DEVIVO JOSEPH President & CEO | Sale 10b5-1 plan | 3,169 | $31.8K |
| Sep 22, 2026 | DEVIVO JOSEPH President & CEO | Sale 10b5-1 plan | 2,811 | $28.1K |
| Sep 4, 2026 | Carlson Megan CAO and SVP, Finance | Sale | 13,804 | $100.8K |
| Sep 4, 2026 | Cashman Steve Chief Business Officer | Sale | 140,112 | $1.02M |
| Sep 2, 2026 | Caezza Nicholas Deputy General Counsel | Sale | 1,709 | $13.9K |
| Aug 24, 2026 | DEVIVO JOSEPH President & CEO | Gift | 250,000 | $0 |
| Aug 17, 2026 | ROBBINS LARRY Director | Sale | 582,500 | $5.23M |
| Aug 14, 2026 | Phanstiel S. Louise Director | Purchase | 115,200 | $999.5K |
| Aug 14, 2026 | ROBBINS LARRY Director | Sale | 824,700 | $7.17M |
| Aug 13, 2026 | ROBBINS LARRY Director | Sale | 500,000 | $4.62M |
| Aug 13, 2026 | ROBBINS LARRY Director | Sale | 175,300 | $1.55M |
| Aug 13, 2026 | ROBBINS LARRY Director | Sale | 215,233 | $2.05M |
| Aug 11, 2026 | Caezza Nicholas Deputy General Counsel | Sale | 10,000 | $97.5K |
| Aug 10, 2026 | DEVIVO JOSEPH President & CEO | Sale 10b5-1 plan | 68,346 | $684.1K |
| Aug 3, 2026 | ROBBINS LARRY Director | Sale | 156,163 | $1.27M |
| Jul 31, 2026 | Carlson Megan CAO and SVP, Finance | Sale | 68,852 | $541.4K |
| Jul 31, 2026 | ROBBINS LARRY Director | Sale | 1,720,129 | $12.72M |
| Jul 22, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 496,680 | $3.21M |
| Jul 22, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 72,724 | $470.5K |
| Jul 22, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 36,366 | $235.3K |
| Jul 22, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 54,143 | $350.3K |
| Jul 21, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 753,320 | $5.07M |
| Jul 20, 2026 | Ku Victor Chief Technology Officer | Sale | 48,540 | $318.4K |
| Jul 20, 2026 | DEVIVO JOSEPH President & CEO | Sale | 211,798 | $1.39M |
| Jul 20, 2026 | Doherty John N. EVP, CFO | Sale | 57,136 | $374.8K |
| Jul 20, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 1,177,276 | $7.79M |
| Jul 17, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 1,195,857 | $7.89M |
| Jul 16, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 1,213,634 | $8.60M |
| Jul 16, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 253,867 | $1.80M |
| Jul 15, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 1,730,319 | $12.67M |
| Jul 14, 2026 | ROTHBERG JONATHAN M Director | Sale 10b5-1 plan | 815,632 | $6.29M |
| Jul 7, 2026 | Ku Victor Chief Technology Officer | Sale | 35,649 | $280.7K |
| Jul 7, 2026 | Doherty John N. EVP, CFO | Sale | 55,229 | $434.8K |
| Jul 7, 2026 | DEVIVO JOSEPH President & CEO | Sale | 204,725 | $1.61M |
| Jul 2, 2026 | Carlson Megan CAO and SVP, Finance | Sale | 41,303 | $328.9K |
| Jun 22, 2026 | Phanstiel S. Louise Director | Award | 25,447 | $0 |
| Jun 22, 2026 | Neubauer Caroll H Director | Award | 25,447 | $0 |
| Jun 22, 2026 | Schwartz Erica Director | Award | 25,447 | $0 |
| Jun 22, 2026 | Edelman Elazer R Director | Award | 25,447 | $0 |
| Jun 22, 2026 | ROTHBERG JONATHAN M Director | Award | 25,447 | $0 |
| Jun 22, 2026 | ROBBINS LARRY Director | Award | 25,447 | $0 |
| Jun 8, 2026 | Cashman Steve Chief Business Officer | Sale | 294,680 | $1.37M |
| Jun 5, 2026 | Cashman Steve Chief Business Officer | Sale | 104,781 | $520.1K |
| Jun 2, 2026 | Caezza Nicholas Deputy General Counsel | Sale | 1,733 | $7.8K |
| May 19, 2026 | Neubauer Caroll H Director | Award | 73,170 | $0 |
| May 1, 2026 | Carlson Megan CAO and SVP, Finance | Sale | 110,422 | $524.4K |
| Apr 29, 2026 | Cashman Steve Chief Business Officer | Sale | 147,518 | $724.2K |
| Apr 16, 2026 | Cashman Steve Chief Business Officer | Sale 10b5-1 plan | 200,000 | $1.04M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Butterfly Network, Inc.
Free account. Everything above stays public.
Write why you follow Butterfly Network, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading